Synopsis:
We evaluate the variation of cardiovascular risks of subclinical hypothyroid patients with thyroid hormone replacement therapy by using the Framingham Risk Scoring system. As a result, it was obviously seen that in subclinical hypothyroid patients, just by thyroid hormone replacement therapy, a marked decrease in cardiovascular risk can be obtained.